Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension phase II study of pegylated recombinant human growth hormone in girls with Turner syndrome
CTR20190004Phase 2Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of peg-somatropin in Turner syndrome (TS), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Feb 2018; status: active.
02
Drugs
peg-somatropin
03
Conditions
Turner syndrome (TS)
Beyond the preview
Go deeper on CTR20190004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190004.